Annual report
Open the filing on sec.gov
Arrowhead Pharmaceuticals, Inc. (ARWR)
Nasdaq: ARWR · Pharmaceutical Preparations · Pasadena, CA · filing with the SEC since 1998
The companyfiscal 2026, as filed
Revenue$451M-45.6%
Net income-$717M-2481.4%
Earnings per share$-5.11-51000.0%
Operating cash flow-$272M-251.5%
Cash$62.7M-72.3%
Debtn/a
Shareholders’ equity$50.5M-90.0%
Shares, diluted141.6M+5.9%
Return on equity-1420.0%
The recordfrom its filings
Filings in 202662
Newest filingNov 12 · 10-K
Annual reportNov 12, 2026
Quarterly reportAug 4, 2026
Next report due10-Q by Feb 9
Insider sales, 12 months$38.0M
Insider buys, 12 months$0.00
Patents granted134
Filer categoryLarge accelerated filer
Trailing twelve months to Sep 2026Revenue $451MNet income -$717MCash from operations -$272Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
The company now
Arrowhead reported revenue of $75.3 million for the quarter ended 30 June 2026, up from $27.8 million a year earlier 2.
Partner payments drove it: $26.4 million from Sarepta, $20.2 million from Novartis and $25.0 million from Madrigal 2.
The operating loss for the quarter was $170.1 million, as research and development spending reached $198.2 million 2.
The company's first approved medicine, REDEMPLO, won FDA approval on 18 November 2025 for familial chylomicronemia syndrome, a rare disease 1.
Two Phase 3 studies of the same medicine in severe hypertriglyceridemia, a higher blood fat condition, met their main goal, the company said 2.
As of Oct 28, 2026. Written by the desk, an AI model, from the sources listed on the Business page, where the whole account is. Nothing here is advice.
Newer filings are on file since this was written; an update is queued.
News
Results released
Open the filing on sec.gov
Large holder update, amended
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Notice of intended sale
Open the filing on sec.gov
Notice of intended sale
Open the filing on sec.gov
Large holder update, amended
Open the filing on sec.gov
Current report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.